Literature DB >> 21880989

Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.

K-E Andersson1.   

Abstract

Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents, both autonomic and somatic, and supraspinal influences from visual, olfactory, and imaginary stimuli. Several central transmitters are involved in the erectile control. Dopamine, acetylcholine, nitric oxide (NO), and peptides, such as oxytocin and adrenocorticotropin/α-melanocyte-stimulating hormone, have a facilitatory role, whereas serotonin may be either facilitatory or inhibitory, and enkephalins are inhibitory. The balance between contractant and relaxant factors controls the degree of contraction of the smooth muscle of the corpora cavernosa (CC) and determines the functional state of the penis. Noradrenaline contracts both CC and penile vessels via stimulation of α₁-adrenoceptors. Neurogenic NO is considered the most important factor for relaxation of penile vessels and CC. The role of other mediators, released from nerves or endothelium, has not been definitely established. Erectile dysfunction (ED), defined as the "inability to achieve or maintain an erection adequate for sexual satisfaction," may have multiple causes and can be classified as psychogenic, vasculogenic or organic, neurologic, and endocrinologic. Many patients with ED respond well to the pharmacological treatments that are currently available, but there are still groups of patients in whom the response is unsatisfactory. The drugs used are able to substitute, partially or completely, the malfunctioning endogenous mechanisms that control penile erection. Most drugs have a direct action on penile tissue facilitating penile smooth muscle relaxation, including oral phosphodiesterase inhibitors and intracavernosal injections of prostaglandin E₁. Irrespective of the underlying cause, these drugs are effective in the majority of cases. Drugs with a central site of action have so far not been very successful. There is a need for therapeutic alternatives. This requires identification of new therapeutic targets and design of new approaches. Research in the field is expanding, and several promising new targets for future drugs have been identified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880989     DOI: 10.1124/pr.111.004515

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  90 in total

Review 1.  Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities).

Authors:  Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

2.  Protein kinase enzymes in the human vagina-relation to key mediators of the cyclic AMP and cyclic GMP pathways.

Authors:  S Ückert; J Sonnenberg; J E Sonnenberg; W Kauffels; K Albrecht; M A Kuczyk; P Hedlund
Journal:  Int J Impot Res       Date:  2017-04-13       Impact factor: 2.896

Review 3.  Impact of Antidepressant Drugs on Sexual Function and Satisfaction.

Authors:  David S Baldwin; Chris Manson; Magda Nowak
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

4.  Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.

Authors:  A S Leitão Junior; R M Campos; J B G Cerqueira; M C Fonteles; C F Santos; G de Nucci; E H S Sousa; L G F Lopes; L F Gonzaga-Silva; N R F Nascimento
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

Review 5.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 6.  Normal male sexual function: emphasis on orgasm and ejaculation.

Authors:  Amjad Alwaal; Benjamin N Breyer; Tom F Lue
Journal:  Fertil Steril       Date:  2015-09-16       Impact factor: 7.329

7.  The sGC activator BAY 60-2770 has potent erectile activity in the rat.

Authors:  George F Lasker; Edward A Pankey; Terrence J Frink; Jonathan R Zeitzer; Korey A Walter; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

8.  Erectile dysfunction and its management in patients with diabetes mellitus.

Authors:  Giuseppe Defeudis; Daniele Gianfrilli; Chiara Di Emidio; Riccardo Pofi; Dario Tuccinardi; Andrea Palermo; Andrea Lenzi; Paolo Pozzilli
Journal:  Rev Endocr Metab Disord       Date:  2015-10-26       Impact factor: 6.514

9.  Enhanced Electrical Field Stimulated Nitrergic and Purinergic Vasoreactivity in Distal vs Proximal Internal Pudendal Arteries.

Authors:  Michael R Odom; Elena S Pak; David A Brown; Johanna L Hannan
Journal:  J Sex Med       Date:  2017-11       Impact factor: 3.802

Review 10.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.